Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Salcaprozic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 3/20 | 0.60 |
| ▸ | NAAA | Q02083 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salcaprozic Acid SCHEMBL825599 | 1.00 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| SCHEMBL253212 | 1.00 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| Salcaprozic Acid SCHEMBL20511604 | 1.00 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| SCHEMBL2331877 | 1.00 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| Salcaprozic Acid SCHEMBL26908047 | 0.97 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| Alcohol SCHEMBL2331970 | 0.95 | NAAA (0.68) | NAAAALOX5HTTALDH1A1TSHR | |
| SCHEMBL4956771 | 0.94 | TSHR (0.61) | NAAAALOX5HTTALDH1A1TSHR | |
| Salcaprozic Acid SCHEMBL29036081 | 0.90 | NAAA (0.65) | NAAAALOX5HTTALDH1A1TSHR | |
| Salcaprozic Acid SCHEMBL29036010 | 0.90 | NAAA (0.65) | NAAAALOX5HTTALDH1A1TSHR | |
| SCHEMBL823552 | 0.87 | NAAA (0.84) | NAAAALOX5HTTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119007-A1 | GROUP OF ANTISENSE OLIGONUCLEOTIDES THAT SPECIFICALLY INHIBIT ANDROGEN RECEPTOR, AND USE THEREOF | 成都凌泰氪生物技术有限公司 | 2025-06-12 | — | — | WO | claimed |
| US-20250367295-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3928776-B1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | SPOKE SCIENCES, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025119007-A1 | GROUP OF ANTISENSE OLIGONUCLEOTIDES THAT SPECIFICALLY INHIBIT ANDROGEN RECEPTOR, AND USE THEREOF | 成都凌泰氪生物技术有限公司 | 2025-06-12 | — | — | WO | disclosed |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | SPOKE SCIENCES, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250120939-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| CN-118141941-B | Abiraterone acetate-containing pharmaceutical composition and preparation method thereof | 深圳市宇健生物医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-118477051-A | Fulvestrant tablet and preparation method thereof | 南京安杰新生物医药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240261408-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4054520-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Novo Nordisk A/S (DK) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-4009957-A1 | SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Novo Nordisk A/S (DK) | 2022-06-15 | — | — | EP | disclosed |
| EP-4009941-A1 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, AN SGLT2 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Novo Nordisk A/S (DK) | 2022-06-15 | — | — | EP | disclosed |
| EP-4009958-A1 | SOLID COMPOSITIONS COMPRISING AN EGF(A) DERIVATIVE AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Novo Nordisk A/S (DK) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022100737-A1 | PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF GLYBURIDE AND PREPARATION METHOD THEREFOR | 江苏先声药业有限公司 | 2022-05-19 | — | — | WO | disclosed |
| WO-2022100736-A1 | PHARMACEUTICAL COMPOSITION OF GLYBURIDE ADMINISTERED NASALLY | 江苏先声药业有限公司 | 2022-05-19 | — | — | WO | disclosed |
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022072864-A2 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | RECEPTOR HOLDINGS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | RECEPTOR HOLDINGS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | ALOX5 206/4885NAAA 39/4885HTT 1270/4885 |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | SLC1A5, SLC43A1, SLC27A2 | ALOX5 330/4885NAAA 152/4885HTT 1152/4885 |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | FAAH, CNR2, FABP2 | ALOX5 206/4885NAAA 39/4885HTT 1270/4885 |
| US-20240261408-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | ALOX5 330/4885NAAA 152/4885HTT 1152/4885 |
| US-20250120939-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | ALOX5 330/4885NAAA 152/4885HTT 1152/4885 |
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | ALOX5 330/4885NAAA 152/4885HTT 1152/4885 |
| US-20250367295-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | ALOX5 330/4885NAAA 152/4885HTT 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.